What it's for (Indications)
- Nizatidine is a histamine H2-receptor antagonist primarily indicated for the treatment and prevention of various acid-related gastrointestinal conditions.
- It is approved for the short-term treatment of active duodenal ulcers, typically for up to eight weeks, and for maintenance therapy to prevent recurrence of duodenal ulcers at a reduced dosage.
- Furthermore, nizatidine is utilized for the treatment of active benign gastric ulcers.
- It also plays a significant role in managing symptoms and healing of erosions associated with gastroesophageal reflux disease (GERD) and erosive esophagitis, which can be caused by the reflux of stomach acid into the esophagus.
- Additionally, nizatidine is indicated for the treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, where there is excessive production of gastric acid.
- Its therapeutic action focuses on reducing gastric acid output, thereby alleviating symptoms and promoting healing of mucosal lesions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of nizatidine must be individualized based on the patient's condition, severity of the disease, and renal function. For active duodenal ulcers, the recommended adult oral dosage is typically 300 mg once daily at bedtime, or 150 mg twice daily. For maintenance therapy of duodenal ulcers, a dosage of 150 mg once daily at bedtime is usually prescribed. In the treatment of active benign gastric ulcers, the recommended dosage is 150 mg twice daily or 300 mg once daily at bedtime for up to 8 weeks. For gastroesophageal reflux disease (GERD) and erosive esophagitis, the standard dosage is 150 mg twice daily. Dosage adjustments are crucial for patients with impaired renal function; for those with a creatinine clearance between 20-50 mL/min, the dosage should be reduced by 50%, and for creatinine clearance less than 20 mL/min, the dosage should be reduced to 75 mg daily. It is imperative to follow prescribing information and consult a healthcare professional for precise dosage regimens. |
Safety & Warnings
Common Side Effects
- Nizatidine is generally well-tolerated, but like all medications, it can cause adverse effects.
- Common side effects reported include headache, dizziness, diarrhea, constipation, nausea, and vomiting.
- Some individuals may experience abdominal pain or dyspepsia.
- Less frequently, but of clinical significance, are hypersensitivity reactions which may manifest as rash, urticaria, pruritus, or angioedema; severe reactions like anaphylaxis, though rare, can occur.
- Transient elevations in liver enzymes (e.
- g.
- , AST, ALT, alkaline phosphatase) have been observed, and rarely, hepatocellular injury.
- Central nervous system effects such as confusion, hallucinations, and somnolence, particularly in elderly patients or those with renal impairment, have been reported.
- Hematologic abnormalities, including reversible thrombocytopenia, are uncommon but have been documented.
- Other rare adverse events include gynecomastia and sexual dysfunction, though these are more commonly associated with other H2-receptor antagonists and are less prominent with nizatidine.
Serious Warnings
- Black Box Warning: Nizatidine does not carry an FDA-mandated Black Box Warning. However, several serious warnings and precautions warrant careful consideration for safe and effective use. **Masking of Malignancy**: Symptomatic response to nizatidine therapy does not preclude the presence of gastric malignancy. It is crucial to rule out gastric carcinoma, especially in middle-aged or older patients with new or recently changed dyspeptic symptoms, before initiating therapy. **Renal Impairment**: Significant dosage adjustments are imperative for patients with impaired renal function to avoid drug accumulation and heightened risk of adverse effects, particularly central nervous system events such as confusion and hallucinations. **Hepatotoxicity**: While rare, transient and reversible elevations in liver enzymes have been reported. Discontinue therapy if significant abnormalities in liver function tests or jaundice develop. **Hypersensitivity Reactions**: Severe hypersensitivity reactions, including anaphylaxis and angioedema, have occurred. Discontinue nizatidine immediately if signs of hypersensitivity appear. **Vitamin B12 Malabsorption**: Prolonged use (over 2 years) of acid-suppressing agents may lead to malabsorption of cyanocobalamin (vitamin B12), potentially resulting in deficiency. Patients on long-term therapy should be monitored. **Risk of *Clostridium difficile* Infection**: Acid-suppressing agents may increase the risk of *Clostridium difficile* associated diarrhea, especially in hospitalized patients. Patients presenting with diarrhea that does not improve should be evaluated. **Central Nervous System Effects**: Confusion, agitation, hallucinations, and delirium have been reported, especially in elderly patients or those with renal dysfunction, necessitating careful patient monitoring. These warnings underscore the importance of careful patient selection, monitoring, and adherence to prescribed dosages.
- Patients should be advised that symptom relief with nizatidine does not exclude the presence of gastric malignancy.
- In cases of gastric ulcer, malignancy should be ruled out prior to initiating therapy, as the medication may mask symptoms.
- Careful dose adjustment is essential for patients with impaired renal function to prevent accumulation of the drug and increased risk of adverse effects, particularly central nervous system disturbances.
- Caution should also be exercised in patients with hepatic impairment.
- Elderly patients may be more susceptible to the central nervous system side effects and often have reduced renal function, necessitating careful monitoring and potential dose adjustments.
- Long-term use of acid-suppressing agents, including nizatidine, has been associated with an increased risk of community-acquired pneumonia and *Clostridium difficile* associated diarrhea.
- Additionally, prolonged therapy (especially over two years) may lead to malabsorption of vitamin B12, potentially resulting in deficiency.
- Patients should be monitored for these potential complications.
How it Works (Mechanism of Action)
Nizatidine functions as a highly selective competitive antagonist of histamine at the H2-receptors located on the gastric parietal cells. By binding to these receptors, it effectively blocks the action of histamine, which is a potent stimulant of gastric acid secretion. This blockade leads to a significant reduction in both basal (non-stimulated) and stimulated gastric acid output. Nizatidine diminishes the volume of gastric secretion and also lowers the hydrogen ion concentration, thereby raising the pH within the stomach. This reduction in acidity is crucial for the healing of peptic ulcers and the alleviation of symptoms associated with gastroesophageal reflux disease (GERD). Unlike some other H2-receptor antagonists, nizatidine has minimal effects on cytochrome P450 enzyme systems, which generally results in fewer drug interactions related to hepatic metabolism. Its specificity for H2-receptors contributes to its therapeutic efficacy in acid-related disorders.
Commercial Brands (Alternatives)
No other brands found for this formula.